TEE
CORT icon

Tibra Equities Europe’s Corcept Therapeutics CORT Stock Holding History

Tibra Equities Europe’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,100
Closed -$236K – 291
2019
Q1 		$236K Buy
20,100
+300
+2% +$3.73K 0.02% 357
2018
Q4 		$265K Buy
+19,800
New +$262K 0.04% 163

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tibra Equities Europe's CORT Position: Q2 2019 in Review

Tibra Equities Europe sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 20,100 shares — an estimated $236K sold.

Tibra Equities Europe first reported a position in CORT in Q4 2018 and held it in 2 quarters. The position peaked at $265K in Q4 2018. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Tibra Equities Europe reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 20,100 Corcept Therapeutics shares in Q2 2019, an estimated $236K.
  • Tibra Equities Europe first reported a position in Corcept Therapeutics in Q4 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Corcept Therapeutics position peaked at $265K in Q4 2018.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.